Hikma revenues grew 9% from $2.3bn to $2.5bn as core operating profit increased by 12% from $566m to $632m.
The EPS remained unchanged and the reported profit which is distributed amongst the shareholders reduced by 2%. Dividend payout for the full year increased by 4 cents.
Hikma Pharma also announced a change in their board of directors on Thursday morning.
Hikma Pharmaceuticals has business divisions: injectables, generic and branded.
Plans for Growth
Hikma launched Advair Diskus last April and is preparing for steady growth and market share through 2022.
The Pharma group plans to expand distribution of specialty products in the US, which includes the launch of a nasal spray, Kloxxado 8mg naloxone.
Injectables are in the process of gaining potential growth by the signing of 2 US biosimilar agreements.
Eight oral oncology products in Algeria have been added to the Branded portfolio.
The Group plans to reduce their greenhouse gas emissions by 25% till 2030.
“Hikma delivered strong financial results in 2021, marking another successful year of solid growth and continued strategic momentum. Our operational strength and high quality standards ensured our ability to provide customers with a consistent supply of essential medicines in a challenging environment. I am grateful to Hikma colleagues around the world for their steadfast commitment to helping the millions of patients who rely on our medicines every day,” said Siggi Olafsson, Chief Executive Officer of Hikma.
“As we look to 2022 and beyond, I am most excited about how we are continuing to build and evolve our portfolio with important investments and new partnerships. Our Injectables business is now supplying US hospitals with sterile compounded pharmaceutical products, has expanded into Canada, and is set to grow further with the acquisition of Custopharm and our expansion into US biosimilars. Our Generics business is bringing more complex and specialty products to market, launching Kloxxado and generic Advair Diskus in 2021, and with additional product launches planned for this year. Our Branded business is delivering consistent growth, with an increased focus on medications to treat chronic illnesses. We have an exciting platform that will drive continued growth and progress in the year ahead.”
